Results 121 to 130 of about 5,890 (202)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia). [PDF]

Clin Infect Dis, 2021
Gómez MA, Navas A, Prieto MD, Giraldo-Parra L, Cossio A, Alexander N, Gore Saravia N.   +6 more
europepmc   +1 more source

AgNP-PVP-meglumine antimoniate nanocomposite reduces Leishmania amazonensis infection in macrophages. [PDF]

BMC Microbiol, 2021
Gélvez APC, Diniz Junior JAP, Brígida RTSS, Rodrigues APD.   +3 more
europepmc   +1 more source

Owners' experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study [PDF]

BACKGROUND: This study examined the experiences of owners of dogs with leishmaniosis who treated their dogs with daily subcutaneous meglumine antimoniate injections.
Broere, Femke, van Eijk, Demy, de Jong, Marja K, Piek, Christine J   +3 more
core  

Effectiveness of harmaline along with meglumine antimoniate on <i>Leishmania major</i>. [PDF]

Vet Res Forum
Ghafourzadeh M, Mirzaie M, Sharifi I, Keyani A, Salarkia E.   +4 more
europepmc   +1 more source

Neutrophil Activation: Influence of Antimony Tolerant and Susceptible Clinical Strains of L. (V.) panamensis and Meglumine Antimoniate. [PDF]

Front Cell Infect Microbiol, 2021
Fernández OL, Ramírez LG, Díaz-Varela M, Tacchini-Cottier F, Saravia NG.   +4 more
europepmc   +1 more source

Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate. [PDF]

Sci Rep
Kenzerki RE, Karamian M, Sharifi I, Pardakhty A, Kheiri H, Salarkia E, Keyhani A.   +6 more
europepmc   +1 more source

Low doses of 3-phenyl-lawsone or meglumine antimoniate delivery by tattooing route are successful in reducing parasite load in cutaneous lesions of Leishmania (Viannia) braziliensis-infected hamsters. [PDF]

Front Cell Infect Microbiol, 2023
Meira RMV, Gomes SLDS, Schaeffer E, Da Silva T, Brito ACS, Siqueira LM, Inácio JD, Almeida-Amaral EE, Da-Cruz AM, Bezerra-Paiva M, Neves RH, Rodrigues LS, Dutra PML, Costa PRR, da Silva AJM, Da-Silva SAG.   +15 more
europepmc   +1 more source

Development of a predictive model for meglumine antimoniate treatment failure in patients with cutaneous leishmaniasis: Aretrospective cohort study. [PDF]

PLoS Negl Trop Dis
Ríos-Echavarría S, Hernández Herrera G, García García HI, López-Carvajal L, Serna-Higuita LM.   +4 more
europepmc   +1 more source

Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a Leishmania braziliensis-endemic area. [PDF]

Front Cell Infect Microbiol, 2022
Barroso DH, Gonçalves RT, Barbosa JS, da Motta JOC, Freire GSM, Gomes CM, Sampaio RNR.   +6 more
europepmc   +1 more source

Comparison of efficacy of intravenous versus intramuscular injection meglumine antimoniate in patients of cutaneous leishmaniasis. [PDF]

Pak J Med Sci
Ahmad N, Shaikh S, Khan SA, Saeed M.
europepmc   +1 more source